

Role of human Pegivirus infections in whole *Plasmodium falciparum* sporozoite vaccination and controlled human malaria infection in African volunteers

Anneth-Mwasi Tumbo

Ifakara Health Institute <https://orcid.org/0000-0002-9992-8073>

Tobias Schindler

Schweizerisches Tropen- und Public Health-Institut

Jean-Pierre Dangy

Schweizerisches Tropen- und Public Health-Institut

Nina Orlova-Fink

Schweizerisches Tropen- und Public Health-Institut

Jose Raso Bieri

Equatorial Guinea Malaria Vaccine Initiative

Maximillian Mpina

Ifakara Health Institute

Florence A. Milando

Ifakara Health Institute

Omar Juma

Ifakara Health Institute

Ali Hamad

Ifakara Health Institute

Elizabeth Nyakarungu

Ifakara Health Institute

Mwajuma Chemba

Ifakara Health Institute

Ali Mtoro

Ifakara Health Institute

Kamaka Ramadhan

Ifakara Health Institute

Ally Olotu

Ifakara Health Institute

Damas Makweba

Loading [MathJax]/jax/output/CommonHTML/jax.js

Stephen Mgaya

Tanzania Commission for Science and Technology

Kenneth Stuart

Seattle Children's Research Institute

Matthieu Perreau

Centre Hospitalier Universitaire Vaudois-Division of Immunology and allergy.

Jack T. Stapleton

Iowa City Veterans Administration and University of Iowa

Said Jongo

Ifakara Health Institute

Stephen L. Hoffman

Sanaria Inc

Marcel Tanner

Schweizerisches Tropen- und Public Health-Institut

Salim Abdulla

Ifakara Health Institute

Claudia Daubenberger (✉ claudia.daubenberger@swisstph.ch)

Schweizerisches Tropen- und Public Health-Institut <https://orcid.org/0000-0001-7136-0642>

Research

Keywords: Malaria, human pegivirus, controlled human malaria infection, immune activation, antibody response, PfSPZ Vaccine

Posted Date: January 22nd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-64109/v2>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on January 26th, 2021. See the published version at <https://doi.org/10.1186/s12985-021-01500-8>.

Abstract

Background: Diverse vaccination outcomes and protection levels among different populations pose a serious challenge to the development of an effective malaria vaccine. Co-infections are among many factors associated with immune dysfunction and sub-optimal vaccination outcomes. Chronic, asymptomatic viral infections can contribute to the modulation of vaccine efficacy through various mechanisms. Human Pegivirus-1 (HPgV-1) persists in immune cells thereby potentially modulating immune responses. We investigated whether Pegivirus infection influences vaccine-induced responses and protection in African volunteers undergoing whole *P. falciparum* sporozoites-based malaria vaccination and controlled human malaria infections (CHMI).

Methods: HPgV-1 prevalence was quantified by RT-qPCR in plasma samples of 96 individuals before, post vaccination with PfSPZ Vaccine and after CHMI in cohorts from Tanzania and Equatorial Guinea. The impact of HPgV-1 infection was evaluated on (1) systemic cytokine and chemokine levels measured by Luminex, (2) PfCSP-specific antibody titers quantified by ELISA, (3) asexual blood-stage parasitemia pre-patent periods and parasite multiplication rates, (4) HPgV-1 RNA levels upon asexual blood-stage parasitemia induced by CHMI.

Results: The prevalence of HPgV-1 was 29.2% (28/96) and sequence analysis of the 5' UTR

and E2 regions revealed the predominance of genotypes 1, 2 and 5. HPgV-1 infection was associated with elevated systemic levels of IL-2 and IL-17A. Comparable vaccine-induced anti-PfCSP antibody titers, asexual blood-stage multiplication rates and pre-patent periods were observed in HPgV-1 positive and negative individuals. However, a tendency for higher protection levels was detected in the HPgV-1 positive group (62.5%) compared to the negative one (51.6%) following CHMI. HPgV-1 viremia levels were not significantly altered after CHMI.

Conclusions: HPgV-1 infection did not alter PfSPZ Vaccine elicited levels of PfCSP-specific antibody responses and parasite multiplication rates. Ongoing HPgV-1 infection appears to improve to some degree protection against CHMI in PfSPZ-vaccinated individuals. This is likely through modulation of immune system activation and systemic cytokines as higher levels of IL-2 and IL17A were observed in HPgV-1 infected individuals. CHMI is safe and well tolerated in HPgV-1 infected individuals. Identification of cell types and mechanisms of both silent and productive infection in individuals will help to unravel the biology of this widely present but largely under-researched virus.

Background

Vaccination is an invaluable tool in public health that has contributed to control of many, and in some cases, to the elimination of infectious disease like smallpox [1]. Malaria, a disease caused by *Plasmodium* species remains a major public health burden particularly in the tropics and sub-tropical regions where it accounted for approximately 405,000 deaths in 2018 [2]. A major goal in malaria

Loading [MathJax]/jax/output/CommonHTML/jax.js e that complements currently used control tools based on

vector control and treatment of clinical malaria infections [3]. However, these vaccine development efforts are challenged by an incomplete understanding of the immune mediators leading to highly protective, long-lasting vaccine induced immunity in the field [4]. A number of studies testing cryopreserved, purified, metabolically active and radiation-attenuated whole sporozoites of *P. falciparum* as vaccine approach (PfSPZ Vaccine) have been published recently [5]–[9]. Strikingly, the comparison of PfSPZ vaccine-induced antibody titers specific for the *P. falciparum* circumsporozoite protein (PfCSP) showed significantly lower titers in malaria pre-exposed than malaria-naive individuals immunized with the PfSPZ Vaccine using comparable regimen [6]–[9]. These differences in PfSPZ vaccine-induced immunity was also observed between vaccinees residing in malaria endemic countries including Tanzania, Mali and Equatorial Guinea [10]–[12].

Recently our group demonstrated that age, location and iron status influence the immune system development of children as well as vaccine-induced responses to the most advanced malaria vaccine candidate, the RTS,S [13]. Additionally, communicable and non-communicable diseases have been implicated in suboptimal vaccine-induced responses [14]. Chronic, asymptomatic viral infections at time of immunization might contribute to reduced magnitude and longevity of vaccine-induced immune responses [15]–[17]. To date, the number of human viruses investigated in this context is limited and their mechanisms in modulation of vaccine-induced responses remain unclear.

Human Pegivirus-1 (HPgV-1), a predominantly asymptomatic virus causing a chronic infection, is common in Africa where an estimated 18-28% of its roughly 750 million global infections occur [18]. The virus establishes its persistence potentially by replicating in immune cells including T cells, B cells, monocytes, and natural killer (NK) cells [19, 20]. Interestingly, seminal field studies have linked HPgV-1 co-infection status to significant survival advantages in HIV-1 and Ebola infected humans [21]–[24]. These favourable outcomes are thought to be based on immune-modulatory properties of HPgV-1 such as reduced activation of T cells, B cells and NK cells [20, 25] and the altered regulation of cytokine and chemokine expression [26]–[28]. Different HPgV-1 genotypes might influence the extent of immune modulation resulting in varied disease outcomes [21]–[23].

Given the high prevalence of HPgV-1 infection in *P. falciparum* endemic countries, we expected an overlapping geographical distribution and aimed to investigate within-host interactions between the two infections. We were therefore interested to study whether HPgV-1 infection status might influence PfSPZ vaccine-induced immune responses. We characterized prevalence and genotype distribution of HPgV-1 in three cohorts of adult volunteers participating in PfSPZ Vaccine studies [9, 29, 30]. We explored the influence of HPgV-1 infection status on cytokine and chemokine levels in serum and correlated HPgV-1 antibody titers and protection against homologous CHMI. We

also aimed to characterize for the first time the potential impact of a CHMI study on HPgV-1 viremia in these volunteers.

Methods

Study population

We used samples from volunteers enrolled in four studies conducted in Bagamoyo, Tanzania (acronyms BSPZV1, BSPZV2, and BSPZV3a) and on Bioko Island in Equatorial Guinea (acronym EGSPZV2) registered at [Clinicaltrials.gov](https://clinicaltrials.gov) with registration numbers [NCT03420053](https://clinicaltrials.gov/ct2/show/study/NCT03420053), [NCT02132299](https://clinicaltrials.gov/ct2/show/study/NCT02132299), [NCT02613520](https://clinicaltrials.gov/ct2/show/study/NCT02613520), and [NCT02859350](https://clinicaltrials.gov/ct2/show/study/NCT02859350), respectively. Detailed trial designs and study procedures such as pre-defined inclusion and exclusion criteria have been described previously [9, 10, 29, 30]. Briefly, these trials evaluated the safety, immunogenicity and efficacy of live, cryopreserved, purified, whole *P. falciparum* sporozoites in malaria pre-exposed volunteers. The analyses in these studies were performed on samples collected from adult volunteers in which vaccine efficacy was evaluated by homologous CHMI based on direct intravenous inoculation of 3200 fully infectious, aseptic purified cryopreserved *P. falciparum* sporozoites. The current study was performed in two parts i) a pilot virome study that included samples from a subset of volunteers from BSPZV1 ([NCT03420053](https://clinicaltrials.gov/ct2/show/study/NCT03420053)) (Supplementary Fig. 1); ii) the main study which utilized samples from volunteers participating in the BSPZV2 ([NCT02132299](https://clinicaltrials.gov/ct2/show/study/NCT02132299)), BSPZV3a ([NCT02613520](https://clinicaltrials.gov/ct2/show/study/NCT02613520)), and EGSPZV2 ([NCT02859350](https://clinicaltrials.gov/ct2/show/study/NCT02859350))_trials. Samples were selected based on availability and scientific aims. Tested sample types and sizes are described in further detail in each section and in Supplementary Fig. 1A.

Identification of Human Pegivirus RNA in RNA-seq data from whole blood

Whole venous blood samples were used from a subset of participants (n=28) (Supplementary Fig. 1A) participating in the BSPZV1 vaccine trial ([NCT03420053](https://clinicaltrials.gov/ct2/show/study/NCT03420053)) based on their availability. All volunteers were healthy males, aged 18 to 35 years and confirmed as negative for HIV-1, Hepatitis B and C at enrolment. Venous blood was collected at different time points including: before vaccination (baseline), 2 and 7 days after first vaccination, 7 days after the second vaccination, before CHMI, 2 and 9 days after CHMI. Each of the placebo (n=6) and the vaccine (n=22) participants had a total of 3 and 7 blood sampling time points screened respectively, resulting in 172 samples in total. All blood samples (n=172) were stored in Paxgene RNA tubes and subjected to RNA-seq analysis performed as published [31]. Briefly, RNA-seq data was generated from whole blood RNA (depleted for globin/rRNA) that was fragmented; the first strand cDNA synthesis was done by random priming and dTTP was used, whereas 2nd strand cDNA synthesis used dUTP which eliminates 2nd strands in the downstream PCR amplification that enabled strand specific RNA-seq sequencing [31]. From the RNA-seq sample set (n=172), 800 million non-human reads were identified. Given the naturally occurring fluctuation of viremia of many viruses, we performed a longitudinal assessment of viral infection status, and obtained reads from all available time points for

Loading [MathJax]/jax/output/CommonHTML/jax.js performed in an in-house developed viral metagenomics

analysis pipeline outlined in (Supplementary Fig. 1 B–C). The pipeline is a combination of several published algorithms adapted from commonly used viral metagenomic analytical tools [32]–[36]. Briefly, our analyses were carried out in three consecutive steps: viral identification, *in silico* validation and RT-PCR confirmation. In the viral identification step, we analysed approximately 3 million non-human, unmapped paired end reads from each volunteer. The initial reads were first searched for “suspected” viral hits by running bowtie2 against the NCBI database containing more than 7424 viral genomes. Thereafter, low quality and complexity reads as well as reads mapping to human genome, transcriptome and repeat regions were removed from the resulting “suspected” viral reads using bowtie2, knead data and tandem repeat finder algorithms, respectively. The “clean” viral reads were then comprehensively searched for viral hits using virome scan [32] and Taxonomer [33] and for viral proteins using adapted Diamond tool containing a custom made database with more than 100,000 viral proteins [35]. The initial unmapped reads were also analysed by Fast virome explorer without filtering for host reads to allow the identification of endogenous retroviral elements and other viruses that may have been missed previously [34]. Only viral hits known to be associated with a human host were selected, and viral contaminants such as lymphotropic murine virus and synthetic constructs coding for either HIV-1 or hepatitis B were removed based on documented literature [37]. In a following *in-silico* confirmatory step, the suspected viral hits were blasted and mapped against specific viral whole genomes using a Geneious bioinformatics tool [38]. As a last step, we performed reverse transcription PCR (RT-PCR) analysis. Due to limited sample availability we were unable to screen the entire BSPZV1 cohort for HPgV-1. Hence, the presence of the most prevalent virus (human pegivirus-1, HPgV-1) was confirmed by RT-PCR in plasma samples of volunteers found positive by RNA-seq transcriptome analysis only.

RT-qPCR for detection and quantification of HPgV-1 and HPgV-2

Plasma samples collected from male and female individuals (n=96), aged 18-45 years, and participating in the BSPZV2, BSPZV3a and the EGSPZV2 studies were included. Plasma was prepared by density gradient centrifugation of whole blood and cryopreserved. At analysis cryopreserved plasma was thawed and used for detection of HPgV-1 and HPgV-2 RNA in all study participants. Plasma samples collected at 3 time points for each volunteer were included, namely before vaccination (baseline), before CHMI and 28 days after CHMI. Presence or absence of HPgV-1 and HPgV-2 was determined simultaneously using RT-qPCR based on published methods [25]. Briefly, total nucleic acids were extracted from 300 ul plasma using Zymo quick DNA/RNA viral kit (Zymo Research, Irvine, USA) and eluted in 50 ul of DNase/RNase free water. 5 ul of the recovered DNA/RNA solution was used as amplification template together with 2X .Lunar universal one step qPCR master mix (10 ul, 1X), Luna warm start reverse transcriptase enzyme mix (1 ul, 1X) (New England Biolabs, MA, USA) and primers binding to the 5' untranslated regions of HPgV-1 and HPgV-2 (each at 2 ul, 0.4 uM) [25, 39]. In addition, human RNaseP primers were added as internal control. Each sample was run in triplicate in a one-step multiplex RT-qPCR using the CFX96 real time PCR system (Bio-Rad, Hercules, CA, USA). The RT-qPCR cycling conditions were: 55°C for 10 min, 95°C for 1

Loading [MathJax]/jax/output/CommonHTML/jax.js for 1 min. The generated data were uploaded to an in-house

available analysis platform where quantification cycle values (Cq) were calculated automatically [40]. HPgV viral quantification was done as described by Stapleton et al. using *in vitro* transcribed (IVT) viral RNA[25]. In each RT-qPCR experiment, we included a positive (HPgV-1 IVT-RNA), a negative (from HPgV-1 negative volunteer) and a non-template control.

Genotyping of HPgV-1

The Fire Script cDNA kit was used to synthesize cDNA in accordance to manufacture instructions (Solis Biodyne, Tartu, Estonia). Briefly, 5 ul of extracted RNA as described above was added into a master mix containing forward and reverse primers specific to 5' UTR of HPgV-1 (each at 1,1 uM), deoxribonucleotide triphosphate mix (dNTP) (0.5 ul, 500 uM), reverse transcription buffer with DTT (2 ul, X1), RiboGrip Rnase inhibitor (0.5 ul, 1 U/ul), Fire script reverse transcriptase (Solis Biodyne, Tartu, Estonia) (2 ul, 10 U/ul) and RNase free water (9 ul to 20 ul). Amplification conditions included 50 min at 50°C and 10 min at 94°C. 3 ul of cDNA generated by reverse transcription were used for the first round of PCR amplification with forward primer 5'-AAAGGTGGTGGATGGGTGATG-3' [41] and reverse primer 5'-ATGCCACCCGCCCTCACCAGAA-3' combination [41]. 1.2 ul of this amplification product was then used for the nested PCR amplification using the forward primer 5'-AATCCC GGTCAYAYTGGTAGCCACT-3' and reverse primer 5'-CCCCACTGGCZTTGYCAACT-3' combination [41]. Both PCR reactions included primers specific for HPgV-1 (1 ul, 1 uM), firepol master mix (4 ul, X5) (Solis Biodyne, Tartu, Estonia) and RNase free water to a final volume of 20 ul. Cycling conditions were 5 min at 95°C, followed by 28 cycles of 95°C for 30 sec, 56°C for 30 sec and 72 °C for 30 sec with a final extension step at 72°C for 10 min. The E2 region was amplified as described by Souza et al., [42]. The final PCR products from 5' UTR amplification (256 base pairs) and E2 amplification (347 base pairs) were sequenced by the Sanger sequencing method (Microsynth, Switzerland).

HPgV-1 phylogenetic analysis

Nucleotide sequence analysis and phylogenetic analysis was performed with the Geneious software version 8.1.9. Chromatograms were examined for quality, and only sequences with quality threshold above 86% were included in analysis. CLUSTALW algorithm was used to align 5' UTR of HPgV-1 (genotype 1 to 7) available through the NCBI database. Thereafter, phylogenetic trees were constructed by the neighbour joining method and the Kimura two parameter models. The references sequences for 5' UTR of HPgV-1 included AF488786, AF488789, KC618399, KP710602, U36388, JX494177, Y16436, and MF398547 (Genotype 1); AB003289, AF104403, D90600, JX494179, MG229668, JX494180, U4402, U59518 (Genotype 2; 2a), MH000566, U59529, U63715, MH053130 (Genotype 2; 2b); AB008335, KR108695, JX494176, D87714 (Genotype 3); AB0188667, AB021287, HQ3311721 (Genotype 4); AB003292, AF177619 (Genotype 6),

HQ331235, HQ 3312233 (Genotype 7). The hepatitis C nucleotide sequence deposited under AJ132997 was used as an out-group. For the E2 region the sequences were KP701602.1, KM670109, U36380, KP710600, KC618399, AB003291 (Genotype 1); AF121950, MK686596, D90600 (Genotype 2a) and U63715 (Genotype 2b); D87714 (Genotype 3); AB0188667 (Genotype 4); AY949771, KC618401, AY951979 (Genotype 5); AB003292 (Genotype 6). A Chimpanzee HPgV-1 strain deposited under AF70476 was used as an out-group and U4402 (Genotype 2) was used for mapping of our sequences to identify regions of similarity.

Ex vivo cytokine and chemokine measurements

Serum samples available from 44 volunteers collected from EGSPZV2 and BSPZV3a (only HIV-1 negative volunteers) at baseline were used for the assessment of the systemic immune activation status. Cytokine and chemokine concentrations were measured using the Cytokine/Chemokine/Growth Factor 45-Plex Human ProcartaPlex™ Panel 1 (Affymetrix Biosciences, USA) and acquired on a validated Luminex XMAP technology platform as described [43]. The investigated cytokines and chemokines included BDNF, Eotaxin/CCL11, EGF, FGF-2, GM-CSF, GRO alpha/CXCL1, HGF, NGF beta, LIF, IFN alpha, IFN gamma, IL-1 beta, IL-1 alpha, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8/CXCL8, IL-9, IL-10, IL-12 p70, IL-13, IL-15, IL-17A, IL-18, IL-21, IL-22, IL-23, IL-27, IL-31, IP-10/CXCL10, MCP-1/CCL2, MIP-1 alpha/CCL3, MIP-1 beta/CCL4, RANTES/CCL5, SDF-1 alpha/CXCL12, TNF alpha, TNF beta/LTA, PDGF-BB, PLGF, SCF, VEGF-A and VEGF-D. Only cytokines and chemokines with levels above the pre-defined lower detection limit of the specific standard curves were included in the group comparisons. Absolute concentrations were normalized to account for the inter-plate variations before analysis in R software version 3.5.1.

Serological analysis

Serum samples for anti-PfCSP antibody evaluation were collected before vaccination (baseline) and 14 days post last vaccination. Anti-PfCSP total IgG levels were measured by enzyme linked immunosorbent assay (ELISA) as described previously [9, 10, 29, 30].

Quantitative detection of *Plasmodium falciparum*

Asexual blood-stage malaria parasitemia during CHMI was assessed using thick blood smear (TBS) microscopy and retrospectively analysed using stored whole blood samples and qPCR as described [9, 10, 29, 30]. Whole blood samples for the assessment of parasitemia were taken before CHMI and during the observation period beginning at day 9 after parasite challenge inoculation until volunteers either became asexual blood-stage malaria positive or until day 21. TBS were performed twice a day from day 9

Loading [MathJax]/jax/output/CommonHTML/jax.js

TBS were also performed on day 28 before malaria drug

treatment. Pre-patent periods were calculated from the time of PfSPZ challenge to first positivity detected by qPCR and TBS [9, 10, 29, 30]. Parasite multiplication rate (PMR) was assessed using a linear model fitted to log₁₀-transformed qPCR data as published [44]. PMR was calculated for all volunteers that developed asexual blood-stage parasitemia which lasted for at least two 48-hour cycles [44].

Statistical analysis

Figures and statistical analyses were generated in R version 3.5.1 and GraphPad Software (Prism V5). Wilcoxon rank sum test or Mann-Whitney test were used to compare continuous variables. Chi-square test was used to compare categorical variables. Absolute values for antibody titers and concentrations of cytokines and chemokines were plotted. Data were log transformed only when investigating the anti-PfCSP antibody titres and viremia levels. Spearman correlation was used to investigate the potential effect of HPgV-1 infection status and viremia with antibody titres and cytokine levels. Data for cytokines, chemokines and growth factors were not analysed for multiple correction as we considered this question as exploratory. P-value ≤ 0.05 was considered significant. Differences in viral diversity, abundance and prevalence were assessed using Linear discriminant analysis effect size [45] and GraphPad Software (Prism V5), respectively.

Results

Unbiased search for RNA molecules encoding human viruses

We aimed to identify viruses present in peripheral blood of our volunteers participating in PfSPZ Vaccine studies. These analyses included samples from 28 participants of the BSPZV1 study collected at multiple time points including baseline, 2 days after first vaccination, 7 days after the first and second vaccination and before CHMI, 2 and 9 days after CHMI. Sequences were identified from a pool of RNA-seq data reads that did not map to the human reference transcriptome. A total of 800 million non-human RNA-seq reads derived from 172 whole blood samples were analysed with our virome discovery platform based on previously established metagenomics pipelines and tools (Supplementary Fig. 1B-C) [32]–[35].

In total, RNA molecules encoding 9 human viruses were detectable including the Human simplex virus (HSV-1), Cytomegalovirus (CMV), Epstein-Barr virus (EBV), Merkel cell polyomavirus (MCV), Human mast adenovirus (HAdV), Astrovirus MBL2, Human betaherpesvirus 7 (HHV-7), Human endogenous retrovirus K113 (HERV-K113) and HPgV-1 (Fig. 1A). The number of reads for each of the identified viruses was quantified and is given in Fig. 1B. After identifying 9 different viruses present in 172 whole blood samples, we further assessed the distribution of viruses within our cohort. HERV-K113 was detected with high number of reads in all 28 individuals, while HSV-1 and CMV were present in seven and six individuals, respectively (Fig. 1C). MBL2, HHV-7 and HAdV were present in low read counts in one individual each, and MCV was found in two individuals. Eight individuals carried HPgV RNA with read

Loading [MathJax]/jax/output/CommonHTML/jax.js three out of 8 HPgV-positive individuals were co-infected with

CMV (Fig. 1C). Our analysis showed that a high proportion of Tanzanian adults (28.6%, 8/28) harboured HPgV -1 infection. To reconfirm our findings, we extracted RNA from plasma samples collected from these 8 volunteers and amplified HPgV-1 by RT-PCR. We reconfirmed in 2 out of 8 volunteers the *in silico* identified presence of HPgV-1 RNA. Interestingly, these 2 volunteers had the highest RNA read counts for HPgV-1 in our bioinformatics analysis (Fig. 1C). These results were important for selecting HPgV-1 as our further research focus and the optimization of RT-PCR assay used for assessment of HPgV-1 infection status in the main study described below.

Prevalence of HPgV-1 in East and West African volunteers

After having established that HPgV-1 is highly present in our Tanzanian cohort (BSPZV1), we aimed to explore the prevalence of HPgV-1 and HPgV-2 in two larger cohorts from Tanzania (BSPZV2 and BSPZV3a) and one from Equatorial Guinea (EGSPZV2). Plasma samples collected from 96 participants, including 12 HIV-1 positive individuals, were analysed for presence of HPgV-1 and HPgV-2 using optimized RT-qPCR. The overall prevalence of HPgV-1 was 29.2 % (28/96) (Fig. 2A), while HPgV-2 was not detected. The proportion of HPgV-1 positive individuals by gender and geographic location were comparable, with slightly more HPgV-1-positive individuals in Equatorial Guinea (31.4%) than Tanzania (26.7%) (Fig. 2 B-C). Of the 12 HIV-1 positive individuals from the BSPZV3a study, two (16.7%, 2/12) were positive for HPgV-1 (Fig. 2D).

HPgV-1 viral loads and distribution

Next, we quantified the HPgV-1 viral load in plasma samples using RT-qPCR. HPgV-1 viral loads were comparable between individuals from the two countries (Fig. 3A). However, based on viral loads with a predefined threshold of 10^6 viral RNA copies/ml of plasma, both cohorts could be divided into HPgV-1 low and high viremic individuals (Fig. 3B). High and low HPgV-1 viremia were found in 17 (60%) and 11 (40%) of the 28 HPgV-1 positive volunteers, respectively (Fig. 3B). Of the 17 high viremic individuals, 8 were from Tanzania and 9 from Equatorial Guinea. Of the 11 low viremic individuals, 4 were Tanzanians and 7 Equatorial Guineans.

No differences in HPgV-1 viral loads between Equatorial Guinea (green, n=16) and Tanzania (blue, n=12) volunteers **(A)**. Two distinct groups with low (blue) and high (grey) viremia levels in plasma are found in HPgV-1 infected individuals **(B)**. The two groups were divided based on a cut off value of 600,000 RNA copies/ml plasma.

Genotyping of HPgV-1 isolates

Seven different genotypes of HPgV-1 have been described globally with genotype 1 and 5 being highly prevalent in sub-Saharan Africa [26]. Therefore, we determined the phylogenetic relatedness of the isolates by amplifying and sequencing the 5' UTRs. From the 28 positive individuals, 2 were excluded due to poor quality of the sequences obtained. Genotype 1 was found in 2 volunteers (7.7%) and surprisingly, genotype 2, described as dominant in Europe and America, was found in 24 of 26 volunteers (92.3%) (Fig. 4). Most genotype 2 strains clustered closely with the related genotype 2a sequences described from Venezuela (Fig. 4). To further increase the resolution of the genetic relatedness of our isolates, we amplified in addition the polymorphic E2 region of HPgV-1. E2 RNA was successfully amplified and sequenced in 9 of the 28 positive volunteers (32%). According to the E2-sequences of our HPgV-1 isolates, our strains clustered within genotypes 1, 2, and 5 (Fig. 5). Notably, genotypic clustering of isolates 6EG and 14EG differed based on E2 and 5' UTR derived PCR products (Fig. 4, 5). In summary, these results show that a range of HPgV-1 genotypes are circulating in Tanzania and Equatorial Guinea, clustering to published genotypes 1, 2 and 5.

Phylogenetic tree was constructed using Neighbour joining method and Kimura two-parameter model of the 5' UTR. The 5' UTR sequences from Tanzania and Equatorial Guinea (n=26) were compared to selected references spanning genotype 1 to 7 from different countries available in the NCBI database. The accession numbers for the reference sequences were: AF488786, AF488789, KC618399, KP710602, U36388, JX494177, Y16436, and MF398547 (Genotype 1, Pink); AB003289, AF104403, D90600, JX494179, MG229668, JX494180, U4402, U59518 (Genotype 2; 2a light brown), MH000566, U59529, U63715, MH053130 (Genotype 2; 2b Brown); AB008335, KR108695, JX494176, D87714 (Genotype 3, Green); AB0188667, AB021287, HQ3311721 (Genotype 4, Maroon); DQ117844, AY949771, AF488796, AF488797 (Genotype 5, Light blue), AB003292, AF177619 (Genotype 6, Bright green); HQ331235, HQ 3312233 (Genotype 7, Golden) and Hepatitis C (AJ132997, Black) was used as outgroup.

Phylogenetic tree was constructed using Neighbour joining method and Kimura two-parameter model of the E2 region of HPgV-1. The E2 sequences from Tanzania and Equatorial Guinea (n=9) were compared to selected references spanning genotype 1 to 6 from different countries available in the NCBI database including; KP701602.1, KM670109, U36380, KP710600, KC618399, AB003291 (Genotype 1, Pink); AF121950, MK686596, D90600 (Genotype 2; 2a Brown), U63715 (Genotype 2; 2b Brown) D87714 (Genotype 3, Green); AB0188667 (Genotype 4, Brown); AY94977, KC618401, AY951979 (Genotype 5, Light blue) and AB003292 (Genotype 6, Green). Equatorial Guinean and Tanzanian strains identified in this study are denoted by strain number followed with letters EG or TZ, respectively (Red). Chimpanzee HPgV-1 strain (AF70476, Black) was used as outgroup and U4402 (Genotype 2, Golden) was used for mapping of our sequences to identify regions of similarity. The scale bar under the tree indicates nucleotide substitution per site.

Effect of HPgV-1 positivity on systemic cytokine and chemokine levels

To dissect whether ongoing HPgV-1 infection affects cytokine and chemokine levels in serum, we measured 45 cytokines, chemokines and growth factors in a subset of 44 volunteers from BSPZV3a (HIV-1 negative only) and EGSPZV2. 23 cytokines, chemokines and growth factors were detected above their pre-defined lower limits of detection (Supplementary Table 1). Although there was a trend of overall higher cytokine levels in HPgV-1 infected individuals (Supplementary Fig. 2), only IL-2 and IL-17A reached significance levels (Fig. 6). There was no statistically significant difference in cytokine and chemokine levels when HPgV-1 high and low viremic individuals were compared (data not shown). Also, we could not find differences in chemokine and cytokine levels when comparing the different HPgV-1 genotypes (data not shown). Taken together, these data suggest that the presence of HPgV-1 infection increases IL-2 and IL-17A levels in peripheral blood.

Cytokine, chemokine and growth factors levels were analysed by Luminex and levels compared between HPgV-1 negative (5' UTR-, grey, n=35) and HPgV-1 positive (5' UTR+, purple, n=9) volunteers. Absolute serum concentrations levels (pg/ml) of Interleukin-2 (IL-2) and Interleukin-17A (IL-17A) at samples taken before vaccination are shown. Significantly higher IL-2 and IL-17A are seen in the HPgV-1⁺ compared to the HPgV-1⁻. Wilcoxon rank sum test was used to determine significance (p-value * < 0.05) which are indicated on top of top for each group comparison.

Effect of HPgV-1 infection status on PfSPZ vaccine-induced humoral immune response

IL-2 and IL-17A might contribute to differentiation of naïve B cells into plasma cells and support the survival of activated B cells [46, 47]. We examined the potential of HPgV-1 infection to impact on PfSPZ vaccine-induced humoral immunity. PfCSP is the most immuno-dominant protein recognized after PfSPZ vaccination. Anti-PfCSP titres were measured at baseline in all volunteers (n=70) and 14 days past last vaccination in all vaccinated volunteers (n=54) participating in BSPZV2, BSPZV3a and EGSPZV2 (Fig. 7 A-B). Similar results were observed when PfSPZ vaccine-induced antibody responses were analysed as net increase (titres at 14 days post last vaccination minus baseline titres) (Fig. 7 C) and as fold change (titres 14 days post last vaccination divided by baseline titres) (Fig. 7 D). There was no significant correlation between HPgV-1 infection status and anti-PfCSP antibody titre at baseline and after vaccination.

Total IgG antibodies recognizing full length PfCSP were measured by ELISA in HPgV-1 negative (5' UTR-, grey), HPgV-1 positive (5' UTR+, purple) volunteers. **A)** Shows baseline (pre-vaccination) anti-PfCSP IgG levels of HPgV-1 negative (n=47) compared to HPgV-1 positive (n=23) volunteers. **B)** Anti-PfCSP IgG levels at 14 days past last vaccination in HPgV-1 positive individuals (n=17) versus the HPgV-1 negative (n=37) group. **(C-D)** Comparison of vaccine-induced changes in anti-PfCSP IgG titres as net responses (14 days post last immunization - baseline) as well as fold (14 days post last vaccination/baseline). Only vaccinated individuals were included for 14 days post last immunization, net and fold change responses. One HPgV-1⁺ individual was not included in these subsequent analyses due to missing antibody data. Log anti-PfCSP titres expressed in arbitrary units are shown. Each point represent an individual, box plot with horizontal bar show median values for each group. Statistical significance was calculated by using Wilcoxon rank sum test (p-value * < 0.05). P values are indicated on top for each group comparison.

Effect of HPgV-1 infection on PfSPZ vaccine efficacy

The high prevalence of HPgV-1 positive volunteers in our cohort allowed us to investigate a potential impact of ongoing viral infection during PfSPZ vaccination on vaccine-induced protection. Protective efficacy of the vaccine was evaluated by presence or absence of asexual blood-stage parasitemia following homologous PfSPZ challenge (CHMI) (Supplementary Fig. 3). While none of the placebo-receiving participants was protected (0/20), the overall protection in the vaccinated group was 55% (26/47). The HPgV-1 prevalence was comparable in these two groups (placebos and vaccines) with 35% (7/20) versus 34% (16/47), respectively, suggesting that HPgV-1 infection does not facilitate protection against CHMI. We further compared the CHMI protection levels in HPgV-1 positive and negative participants in the vaccinated group only (Fig. 8A). HPgV-1 positive vaccinees showed slightly higher protection levels after CHMI (62.5%; 10/16) compared to HPgV-1 negative individuals (51.6%; 16/31). We

Loading [MathJax]/jax/output/CommonHTML/jax.js t the peak response which is 14 days past last vaccination.

Slightly higher anti-PfCSP levels were seen in protected compared to non-protected individuals (Fig. 8B), without reaching statistical significance. PfCSP antibody levels tended to be lower in the HPgV-1 positive individuals (Fig. 8B).

Parasitemia was determined in whole blood by qPCR and thick blood smear microscopy (TBS). The analysis included only placebo participants, positive and negative for HPgV-1. **(A)** Shows log-fold change of parasitemia in 48 hours between HPgV-1 negative (5' UTR-, grey, n=13) and HPgV-1 positive (5' UTR+, purple, n=7) volunteers. **(B)** Comparison of days post CHMI to malaria positivity by microscopy in HPgV-1 negative (5' UTR-, grey, n= 11) and HPgV-1 positive (5' UTR+, purple, n=7). **(C)** HPgV-1 viral loads before (red) and 28 days post CHMI (green) in HPgV-1 infected individuals. Each point represents an individual, box plots show data distribution with horizontal bar denoting viral load at each visit. Lines connect viremia levels in individuals found positive for HPgV-1 on both time points. Geometric means were compared between groups and unpaired t-test was used to calculate significance. Horizontal bars represent mean with standard deviation Wilcoxon rank sum test was used to compare viremia levels before and after CHMI. P-values are indicated on top of each comparison.

Interaction of HPgV-1 and controlled human malaria infection induced asexual blood-stage parasites

HPgV-1 co-infection has been associated with favourable clinical outcomes in HIV-1 and Ebola co-infected individuals [21]–[23]. So far, the HPgV-1 impact on *P. falciparum* infection and immunity is unknown. We evaluated parasite multiplication rates and pre-patent periods in the placebo volunteers only, that have not been vaccinated (n=20) undergoing CHMI. Comparable asexual blood-stage multiplication rates and pre-patent periods were observed between HPgV-1 positive and negative individuals (Fig. 9 A-B).

Effect of CHMI on HPgV-1 viremia levels

P. falciparum infection is known to impact viremia levels of some common viruses like HIV-1 and EBV [48, 49]. We therefore evaluated the effect of an acute *P. falciparum* infection on HPgV-1 viremia by comparing the viral load before and 28 days post CHMI in 21 eligible trial participants. Detectable levels of HPgV-1 at both time points were quantified in 9 individuals; 5 of those showed an increased HPgV-1 viral load and the other 4 had decreased viremia post CHMI (Fig. 9C). In addition, 12 trial participants were HPgV-1 positive only for one of the two tested time points; 6 were positive before CHMI and 6 were positive at 28 days post CHMI (Fig. 9C).

Individuals were treated with either normal saline (placebo) or PfSPZ Vaccine (vaccinees). Presence or absence of malaria parasites was determined in whole blood by thick blood smear microscopy (TBS) and confirmed by qPCR. Total IgG antibodies recognizing full length PfCSP were measured by ELISA. **A)** Proportion of non-protected (cream) and protected (blue) in vaccinated volunteers with and without HPgV-1 infection. Proportions are indicated inside the bar and volunteer numbers on top. **C)** Total anti-CSP IgG levels at 14 days past last vaccination in the protected (malaria negative) and non-protected (malaria positive) groups, with and without HPgV-1 infection. Log anti-PfCSP titres expressed in O.D units are shown. Each point represent an individual, and box plot with horizontal bar show median values for each group. Chi square with Yates correction was used for group comparisons of categorical values (*, $P < 0.05$). Wilcoxon rank sum test was used to compare anti-CSP titres in the two groups. P values are indicated on top of each comparison.

Discussion

The role of chronic asymptomatic viral infections in modulating immune responses in health and disease is increasingly appreciated [50]. The present study sought to better understand the prevalence and genotype distribution of HPgV-1 in East and West-central Africa. We aimed to investigate the potential influence of HPgV-1 infection on experimental malaria vaccine-induced humoral immunity and vaccine-induced protection. By studying a cohort of volunteers undergoing CHMI, we were in a unique position to investigate if an acute malaria episode has an impact on HPgV-1 viremia in chronically infected volunteers.

In a first step, we used an unbiased approach by generating RNA-seq data to identify prevalent viruses circulating in peripheral blood of our BSPZV1 study volunteers that lead to the identification of HPgV-1 as highly present in this group. Confirmation by RT-PCR was possible only in 2/8 HPgV-1 positive volunteers. Several factors might have contributed to these discrepancies in results, such as the volume and type of samples used. 300 ul of plasma was used as starting material for RNA extraction and RT-PCR, while roughly 10 times more whole blood was applied as starting material for the RNA-seq data generation. Also, the variation in HPgV-1 viremia levels between serum and cellular components have been demonstrated previously [19, 25]. The drawbacks of RT-PCR based methods over deep RNA sequencing methods in virus identification have been previously reported. To overcome these limitations, the combination of qPCR working with predefined primers and unbiased deep sequencing approaches is recommended [51, 52]. The unbiased virome analyses were important for focusing our analyses on HPgV-1 in larger cohorts in East and West Africa.

The overall prevalence of HPgV-1 in our main study cohort was 29.2 %, roughly the same for Tanzania and Equatorial Guinea. The prevalence reported here is likely underestimated as we observed fluctuations of HPgV-1 viral loads longitudinally, with some volunteers showing HPgV-1 positivity in one, two or all three time points assessed. These detection variations might indicate either viral clearance or continuously ongoing viral replication with viremia fluctuations sometimes below the lower detection limit of our RT-qPCR assay [19, 25]. We did not detect HPgV-2 RNA in any of our volunteers but we cannot completely exclude the possibility of the presence of circulating HPgV-2 as antibody titers against the HPgV-1 and HPgV-2 E2 envelope proteins were not measured. Our study focussed on the potential impact of HPgV-1 on PfSPZ vaccine induced humoral responses and protection, thus HIV-1 positive individuals of the BSPZV3a study were excluded from the HPgV-1 association analyses. It is well known that HIV-1 infection negatively impacts immunity in widely used routine vaccines [53].

Similar to a study in Mexico, we observed two broad groups, low and high, of HPgV-1 viremic individuals, defined by a cut off value of 600,000 RNA copies/ml. This observation likely reflects the different viral replication states within infected volunteers [22]. We observed similar numbers of high and low viremic individuals, who are infected with HPgV-1 genotype 2. The potential role of a distinct viral genotype on this pattern remains unclear, given the small number of volunteers in this study and limited heterogeneity of the detected HPgV-1 genotypes.

Currently, 7 HPgV-1 genotypes are described globally [54, 55] and some of these genotypes have been implicated in varied clinical outcomes [23, 26, 56]. HIV-1/HPgV-1 co-infection studies revealed lower CD4 T cell counts in individuals infected with HPgV-1 genotype 2a than genotype 2b [56, 57] and higher HPgV-1 viral loads in individuals with genotype 1 compared to genotypes 2a and 2b [58]. Higher serum levels of IFN- γ were described in HIV-1 positive women co-infected with genotype 2 compared to genotype 1 [23].

Phylogenetic analyses in our cohort demonstrated the presence of genotype 1 (n=2, 7.1%) and 2 (n=24, 92.3%). Most of our genotype 2 strains clustered within group 2a, originally described from Venezuela. Genotype 1 and 2 have been previously reported in Tanzania but there are no published data available for Equatorial Guinea [59, 60]. The predominance of genotype 2 in our study is somewhat surprising. Given the diverse geographic origin of our volunteers recruited from East and West-central Africa, we had expected to find higher HPgV-1 genetic diversity. Studies in neighbouring countries including Cameroon, the Democratic Republic of Congo and Gabon revealed a high prevalence of genotype 1 [61]–[65]. Genotypes 2 and 5 were also seen when phylogenetic studies included molecular markers other than 5' UTR region like envelope protein 1 (E1), non-structural protein 3 (NS3) and non-structural protein 5A [62], [66]. The limitations of amplification of the 5' UTR, a highly conserved region, to discriminate closely related isolates is known [67]. Due to its high variability, E2 provides better genotyping resolution compared to 5' UTR. We amplified and sequenced the E2 region from subjects with high viremia levels in

Loading [MathJax]/jax/output/CommonHTML/jax.js these 9 isolates clustered with strains described elsewhere in

Africa. It is possible that the failure to amplify E2 from all volunteers positive by 5' UTR detection is either due to the low sensitivity of the assay used or the high genetic diversity of the E2 region [42]. While it is known that the detection of HPgV-1 based on amplification of the E2 region is highly specific, it requires higher amounts of RNA input [42] and individuals with low HPgV-1 viremia are likely missed. Alternatively, it is possible that E2 genetic variants could not be amplified with the primers used due to nucleotide sequence mismatch. The E2 region is highly variable and this diversity contributes to structural, functional and immunogenic properties of the virus [68]. The inconsistent genotyping results of isolates 6EG and 14EG based on 5' UTR and E2 amplification might be resolved by whole genome sequencing of the virus. Vitrenko et al., reported similar findings in samples from Ukrainian females donating fetal tissues [67].

Cytokines, chemokines and growth factors are important for inter-cellular communication and regulation of immune processes [69]. Any changes in levels of these immune mediators can act as markers of inflammation, immunity or vaccine uptake [26, 70, 71]. We therefore investigated if altered levels of cytokines and chemokines unique to ongoing HPgV-1 infection could be identified. We analysed serum samples taken at baseline for 45 cytokines in a Luminex platform. Volunteers with chemokine and cytokine levels above the lower limit of detection were stratified according to the HPgV-1 infection status. Of all 23 differentially detected cytokines and chemokines, IL-2 and IL-17A were significantly higher in HPgV-1 positive compared to HPgV-1 negative individuals.

IL-2 is an essential survival factor for T and B lymphocytes [47, 72] and induces the development and survival of regulatory CD4 T cells critical for the maintenance of immune tolerance [73]. Fama et al., showed increased levels of circulating soluble IL-2 receptor (sIL-2R) in HPgV-1 positive volunteers but the authors did not quantify IL-2 levels [74]. The increased concentrations of IL-2 seen amongst the HPgV-1 positive individuals could be linked to either on-going antiviral immunity [75] or serves as a survival mechanism used by the virus to establish persistence in immune cells. A similar mechanism has been described in the apicomplexan pathogen *Theileria parva* that infects T and B lymphocytes in cattle [76]. Contrary to our observations are results from HPgV-1/HIV-1 coinfection studies which have shown reduced T-cell activation and IL-2 release in coinfecting individuals [77, 78]. The HPgV-1 envelope protein 2 (HPgV1-E2) has been implicated in these outcomes, due to its ability to inhibit T cell-receptor mediated signalling and IL-2 signalling pathways [77, 78].

IL-17A induction has been associated with bacterial, fungal, autoimmune and inflammatory diseases [79]. IL-17A stimulates production of chemokines such as monocyte chemoattractant protein-1 which mediates tissue infiltration of monocytes. The role of IL-17A in the context of HPgV-1 infection is

Loading [MathJax]/jax/output/CommonHTML/jax.js

like HIV-1 and Hepatitis C, IL-17A has been shown to promote

T-cell mediated anti-viral responses through activation and recruitment of dendritic cells, monocytes and neutrophils [80, 81]. Other cytokines and chemokines which could be detected, albeit not significantly different in HPgV-1 positive individuals included SCF (lower) and IL-1beta, IL-12p70, MCP-1, LIF, VEGF.A, HGF and TNF- α (higher). BDNF, EGF, Eotaxin, GRO-alpha, IFN- γ , IL-7, IP-10, MIP1-a, Mip-1b, PDGF.BB, PIGF.1, RANTES, SDF-1a, and VEGF.D were comparable between the two groups. The levels of these measured cytokines and chemokines are within ranges previously reported [26, 27]. While most of the previous HPgV-1 studies had focused on at risk populations, particularly on HIV-1 positive persons, our investigations are in healthy individuals [26, 74], therefore some of the observed differences could be due to health status.

Here, we observed lower, albeit not statistically significant, median anti-PfCSP titres in the HPgV-1 positive versus the negative group at baseline and 14 days past last vaccination. These observations mirror findings by Avelino-Silva et al., who showed no association between HPgV-1 infection status/viremia with yellow fever specific neutralizing antibody titres in HIV-1 positive individuals immunized with yellow fever vaccine [82]. While studies have extensively tried to understand potential inhibition mechanisms induced by HPgV-1 (and other Flaviviruses) on T cell activation [77, 83], activation pathways that might be affected in B cells are less explored. It is also possible that the effect of HPgV-1 viruses on immune responses against vaccines is negligible when studied singly, but this impact is significantly synergized in the presence of other, co-infecting viruses like EBV, CMV and HSV [85, 86]. Hence, the potential role played by the combined human virome in shaping vaccine-induced responses in different populations needs to be further explored in larger cohorts.

Clinically silent, chronic viral infections are known to modulate host immunity [16] and in turn, acute co-infections are known to drive the re-activation of asymptomatic viral infections [49]. Several viruses, like HIV-1, Ebola and HCV have been implicated in the pathogenesis and clinical outcome of ongoing malaria infections through a range of different mechanisms [84]–[86]. It has been suggested that HIV-1 infections worsen *P. falciparum* presentations by depleting the CD4 T-cell compartment, essential for driving malaria-specific antibody responses and for clearance of malaria infected red blood cells [84]. In contrast, better survival outcomes have been reported in Ebola infected individuals with *P. falciparum* co-infections [85]. Reports have also suggested delayed emergence of *P. falciparum* asexual blood-stages in Gabonese individuals chronically infected with HCV [86]. Thus, we studied the impact of HPgV-1 positivity on asexual *P. falciparum* parasitemia and multiplication rates during CHMI. Vice versa, we also looked for the first time at the impact of PfSPZ vaccination and PfSPZ challenge on HPgV-1 viremia. We could not find evidence of an association between HPgV-1 infection status and asexual blood-stage parasite multiplication rates after CHMI. A slight trend towards longer pre-patent period was seen in HPgV-1 positive individuals. HPgV-1 positivity appears to increase malaria vaccine-induced protection, since slightly higher proportion of CHMI protected individuals were HPgV-1 positive (62.5% vs 51.6%). However,

our study is limited by the sample size and further investigations with larger cohorts are required to corroborate these findings. Importantly, PfSPZ vaccination and PfSPZ challenge did not impact HPgV-1 viremia levels in our cohort suggesting that the conduct of CHMI is safe in HPgV-1 infected volunteers.

Conclusions

Notable effects have been reported in HPgV-1 co-infections with other RNA viruses such as HIV-1 and Ebola. Although our study is constrained with limited sample size, we have highlighted the epidemiology and genetic distribution of HPgV-1 in areas endemic for malaria. We have reported for the first time HPgV-1 genotype distribution in Equatorial Guinea. We examined the potential influence of HPgV-1 infection status on PfSPZ vaccine-induced PfCSP-antibody titres and CHMI outcome without finding any striking correlation. Our study provides first time evidence that intravenous vaccination using large numbers of attenuated *P. falciparum* sporozoites and CHMI does not increase HPgV-1 viremia in already infected volunteers.

List Of Abbreviations

CHMI: Controlled human malaria infection

CSP: Circumsporozoite protein

E1/2: Envelope glycoproteins (1 and 2)

HPgV: Human pegivirus

IVT: In vitro transcription

LEfSe: Linear discriminant analysis effect size

NK: Natural killer cells

NS5A: Non-structural protein 5A

PfCSP: *Plasmodium falciparum* circumsporozoite protein

PfSPZ: *Plasmodium falciparum* sporozite

PMR: Parasite Multiplication Rate

RNaseP: Ribonuclease P

SSA: Sub-Saharan Africa

TBS: Thick blood smear

UTRs: Untranslated regions

Declarations

Ethics approval and consent to participate

The studies were registered at Clinicaltrial.gov. under the registration numbers NCT02132299 (BSPZV1), NCT02613520 (BSPZV2), NCT03420053 (BSPZV3a) and NCT02859350 (EGSPZV2). All clinical trials were approved by the Institutional Review Board for the Ifakara Health Institute (IHI-IRB), Tanzanian Food and Drug Administration (TFDA), Tanzanian National Institute for Medical Research (NIMR) and the Ethical Committee of Northern and Central Switzerland (EKNZ). Written informed consent was obtained from all participants prior enrolment. All trial procedures were conducted in accordance to good clinical practice (GCP) and under the Declaration of Helsinki.

Consent for publication

Not applicable

Availability of data and materials

Data are available from the corresponding author upon reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was funded by Equatorial Guinea Malaria Vaccine initiative. AT is supported by Swiss government, through ESKAS scheme scholarship grant no 2016.0056. KS was supported by NIH grant AI128194.

Authors' contributions

Study concept and design: AT, TS, CD, Investigation: AT, TS, JP, MP, KS, Technical support and resources: Loading [MathJax]/jax/output/CommonHTML/jax.js: AT, TS, NOF, CD, Drafting the manuscript and reviewing: AT,

TS, NOF, CD, and all other authors reviewed the manuscript, Study supervision: CD; AO, SJ, Funding acquisition: CD, MT, KS

Acknowledgements

The authors would like to thank all participants of the clinical trials for their willingness to participate. We extend our appreciation to the clinical and laboratory staff involved in these trials (BSPZV1, BSPZV2, BSPZV3a and EGSPZV2), both at the Ifakara Health Institute in Tanzania and the Malaria Vaccine Initiative in Malabo, Equatorial Guinea. We would also like to thank: Prof. Jack Stapleton (University of Iowa), Prof Laurent Kaiser and Dr. Samuel Cordey (University of Geneva) for providing the plasmids which were used as positive controls and for generating standards for HPgV strains; Ashery Mbilinyi for technical assistance; Tanzania commission of science and technology (COSTECH) for providing us with high performance computing facility.

References

- [1] B. Greenwood, "The contribution of vaccination to global health: past, present and future," *Philos. Trans. R. Soc. Lond., B, Biol. Sci.*, vol. 369, no. 1645, p. 20130433, 2014, doi: 10.1098/rstb.2013.0433.
- [2] "World malaria report 2019." <https://www.who.int/publications-detail/world-malaria-report-2019> (accessed May 20, 2020).
- [3] J. Healer, A. F. Cowman, D. C. Kaslow, and A. J. Birkett, "Vaccines to Accelerate Malaria Elimination and Eventual Eradication," *Cold Spring Harb Perspect Med*, vol. 7, no. 9, Sep. 2017, doi: 10.1101/cshperspect.a025627.
- [4] J. Langhorne, F. M. Ndungu, A.-M. Sponaas, and K. Marsh, "Immunity to malaria: more questions than answers," *Nat. Immunol.*, vol. 9, no. 7, Art. no. 7, Jul. 2008, doi: 10.1038/ni.f.205.
- [5] T. L. Richie *et al.*, "Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines," *Vaccine*, vol. 33, no. 52, pp. 7452–7461, Dec. 2015, doi: 10.1016/j.vaccine.2015.09.096.
- [6] R. A. Seder *et al.*, "Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine," *Science*, vol. 341, no. 6152, pp. 1359–1365, Sep. 2013, doi: 10.1126/science.1241800.
- [7] K. E. Lyke *et al.*, "Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection," *PNAS*, vol. 114, no. 10, pp. 2711–2716, Mar. 2017, doi: 10.1073/pnas.1615324114.

- [8] J. E. Epstein *et al.*, "Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity," *Science*, vol. 334, no. 6055, Art. no. 6055, Oct. 2011, doi: 10.1126/science.1211548.
- [9] S. A. Jongo *et al.*, "Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults," *Am J Trop Med Hyg*, vol. 99, no. 2, Art. no. 2, Aug. 2018, doi: 10.4269/ajtmh.17-1014.
- [10] S. A. Jongo *et al.*, "Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants," *Am. J. Trop. Med. Hyg.*, vol. 100, no. 6, pp. 1433–1444, 2019, doi: 10.4269/ajtmh.18-0835.
- [11] A. Olotu *et al.*, "Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of PfSPZ Vaccine for Malaria in Healthy Equatoguinean Men," *Am J Trop Med Hyg*, vol. 98, no. 1, Art. no. 1, Jan. 2018, doi: 10.4269/ajtmh.17-0449.
- [12] M. S. Sissoko *et al.*, "Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial," *The Lancet Infectious Diseases*, vol. 17, no. 5, Art. no. 5, May 2017, doi: 10.1016/S1473-3099(17)30104-4.
- [13] D. L. Hill *et al.*, "Immune system development varies according to age, location, and anemia in African children," *Sci Transl Med*, vol. 12, no. 529, Feb. 2020, doi: 10.1126/scitranslmed.aaw9522.
- [14] G. de Bruyn, "Cofactors that may influence vaccine responses," *Current Opinion in HIV and AIDS*, vol. 5, no. 5, pp. 404–408, Sep. 2010, doi: 10.1097/COH.0b013e32833d1fca.
- [15] N. Lenz *et al.*, "Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4⁺ T Cells," *Clin Vaccine Immunol*, vol. 22, no. 7, Art. no. 7, Jul. 2015, doi: 10.1128/CVI.00092-15.
- [16] C. S. Rocha *et al.*, "Subclinical Cytomegalovirus Infection Is Associated with Altered Host Immunity, Gut Microbiota, and Vaccine Responses," *Journal of Virology*, vol. 92, no. 13, Art. no. 13, Jul. 2018, doi: 10.1128/JVI.00167-18.
- [17] S. Rodriguez, M. Roussel, K. Tarte, and P. Amé-Thomas, "Impact of Chronic Viral Infection on T-Cell Dependent Humoral Immune Response," *Front Immunol*, vol. 8, Oct. 2017, doi: 10.3389/fimmu.2017.01434.
- [18] S. Singh and J. T. Blackard, "Human pegivirus (HPgV) infection in sub-Saharan Africa-A call for a renewed research agenda," *Rev. Med. Virol.*, vol. 27, no. 6, Art. no. 6, 2017, doi: 10.1002/rmv.1951.

- [19] E. T. Chivero, N. Bhattarai, R. T. Rydze, M. A. Winters, M. Holodniy, and J. T. Stapleton, "Human pegivirus RNA is found in multiple blood mononuclear cells in vivo and serum-derived viral RNA-containing particles are infectious in vitro," *J. Gen. Virol.*, vol. 95, no. Pt 6, Art. no. Pt 6, Jun. 2014, doi: 10.1099/vir.0.063016-0.
- [20] E. T. Chivero and J. T. Stapleton, "Tropism of human pegivirus (formerly known as GB virus C/hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection," *J. Gen. Virol.*, vol. 96, no. Pt 7, Art. no. Pt 7, Jul. 2015, doi: 10.1099/vir.0.000086.
- [21] J. Xiang *et al.*, "Effect of coinfection with GB virus C on survival among patients with HIV infection.," *N Engl J Med*, vol. 345, no. 10, Art. no. 10, Sep. 2001, doi: 10.1056/NEJMoa003364.
- [22] G. Horemheb-Rubio *et al.*, "High HPgV replication is associated with improved surrogate markers of HIV progression," *PLOS ONE*, vol. 12, no. 9, Art. no. 9, Sep. 2017, doi: 10.1371/journal.pone.0184494.
- [23] H. L. Tillmann *et al.*, "Infection with GB virus C and reduced mortality among HIV-infected patients," *N. Engl. J. Med.*, vol. 345, no. 10, Art. no. 10, Sep. 2001, doi: 10.1056/NEJMoa010398.
- [24] M. Lauck, A. L. Bailey, K. G. Andersen, T. L. Goldberg, P. C. Sabeti, and D. H. O'Connor, "GB Virus C Coinfections in West African Ebola Patients," *Journal of Virology*, vol. 89, no. 4, Art. no. 4, Feb. 2015, doi: 10.1128/JVI.02752-14.
- [25] R. T. Rydze, N. Bhattarai, and J. T. Stapleton, "GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T-cell death," *Antivir Ther*, vol. 17, no. 7, Art. no. 7, 2012, doi: 10.3851/IMP2309.
- [26] J. T. Blackard *et al.*, "Cytokine/chemokine expression associated with Human Pegivirus (HPgV) infection in women with HIV," *J Med Virol*, vol. 89, no. 11, Art. no. 11, Nov. 2017, doi: 10.1002/jmv.24836.
- [27] M. C. Lanteri *et al.*, "Downregulation of Cytokines and Chemokines by GB Virus C After Transmission Via Blood Transfusion in HIV-Positive Blood Recipients," *J Infect Dis*, vol. 211, no. 10, Art. no. 10, May 2015, doi: 10.1093/infdis/jiu660.
- [28] G. Nunnari *et al.*, "Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile," *Ann. Intern. Med.*, vol. 139, no. 1, Art. no. 1, Jul. 2003, doi: 10.7326/0003-4819-139-1-200307010-00009.
- [29] S. A. Jongo *et al.*, "Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults," *Clin. Infect. Dis.*, Nov. 2019, doi: 10.1093/cid/ciz1152.
- [30] Jongo *et al.*, "Immunogenicity and protective efficacy of radiation-attenuated and chemo-attenuated 4 PfSPZ vaccines in Equatoguinean adults (Jongo *et al.*, manuscript in press)." .

- [31] J. Hitchen, R. Sooknanan, and A. Khanna, "Rapid and Efficient Methods for Preparing Globin- and rRNA-Depleted Directional RNA-Seq Libraries," *J Biomol Tech*, vol. 24, no. Suppl, pp. S43–S44, May 2013.
- [32] S. Rampelli *et al.*, "ViromeScan: a new tool for metagenomic viral community profiling," *BMC Genomics*, vol. 17, p. 165, Mar. 2016, doi: 10.1186/s12864-016-2446-3.
- [33] S. Flygare *et al.*, "Taxonomer: an interactive metagenomics analysis portal for universal pathogen detection and host mRNA expression profiling," *Genome Biol.*, vol. 17, no. 1, p. 111, 26 2016, doi: 10.1186/s13059-016-0969-1.
- [34] S. S. Tithi, F. O. Aylward, R. V. Jensen, and L. Zhang, "FastViromeExplorer: a pipeline for virus and phage identification and abundance profiling in metagenomics data," *PeerJ*, vol. 6, p. e4227, Jan. 2018, doi: 10.7717/peerj.4227.
- [35] B. Buchfink, C. Xie, and D. H. Huson, "Fast and sensitive protein alignment using DIAMOND," *Nat. Methods*, vol. 12, no. 1, pp. 59–60, Jan. 2015, doi: 10.1038/nmeth.3176.
- [36] G. J. Xu *et al.*, "Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome," *Science*, vol. 348, no. 6239, p. aaa0698, Jun. 2015, doi: 10.1126/science.aaa0698.
- [37] A. Moustafa *et al.*, "The blood DNA virome in 8,000 humans," *PLoS Pathog.*, vol. 13, no. 3, p. e1006292, 2017, doi: 10.1371/journal.ppat.1006292.
- [38] M. Kearse *et al.*, "Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data," *Bioinformatics*, vol. 28, no. 12, pp. 1647–1649, Jun. 2012, doi: 10.1093/bioinformatics/bts199.
- [39] M. Frankel *et al.*, "Development of a high-throughput multiplexed real time RT-PCR assay for detection of human pegivirus 1 and 2," *Journal of Virological Methods*, vol. 241, pp. 34–40, Mar. 2017, doi: 10.1016/j.jviromet.2016.12.013.
- [40] S. Krähenbühl *et al.*, "ELIMU-MDx: a web-based, open-source platform for storage, management and analysis of diagnostic qPCR data," *BioTechniques*, vol. 68, no. 1, pp. 22–27, 2020, doi: 10.2144/btn-2019-0064.
- [41] K. F. N'Guessan *et al.*, "Human pegivirus (HPgV) infection in Ghanaians co-infected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV)," *Virus Genes*, vol. 54, no. 3, Art. no. 3, Jun. 2018, doi: 10.1007/s11262-018-1555-2.
- [42] I. E. Souza *et al.*, "Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia," *J. Clin. Microbiol.*, vol. 44, no. 9, Art. no. 9, Sep. 2006, doi: 10.1128/JCM.02663-05.

- [43] P. Amelio *et al.*, "HIV Infection Functionally Impairs Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses," *Journal of Virology*, p. JVI.01728-18, Dec. 2018, doi: 10.1128/JVI.01728-18.
- [44] A. D. Douglas *et al.*, "Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection," *J Infect Dis*, vol. 208, no. 2, pp. 340–345, Jul. 2013, doi: 10.1093/infdis/jit156.
- [45] N. Segata *et al.*, "Metagenomic biomarker discovery and explanation," *Genome Biol.*, vol. 12, no. 6, p. R60, Jun. 2011, doi: 10.1186/gb-2011-12-6-r60.
- [46] A. Shibui *et al.*, "Th17 cell-derived IL-17 is dispensable for B cell antibody production," *Cytokine*, vol. 59, no. 1, pp. 108–114, Jul. 2012, doi: 10.1016/j.cyto.2012.03.018.
- [47] S. L. Gallou, G. Caron, C. Delaloy, D. Rossille, K. Tarte, and T. Fest, "IL-2 Requirement for Human Plasma Cell Generation: Coupling Differentiation and Proliferation by Enhancing MAPK–ERK Signaling," *The Journal of Immunology*, vol. 189, no. 1, pp. 161–173, Jul. 2012, doi: 10.4049/jimmunol.1200301.
- [48] I. F. Hoffman *et al.*, "The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration," *AIDS*, vol. 13, no. 4, pp. 487–494, Mar. 1999, doi: 10.1097/00002030-199903110-00007.
- [49] A. Reynaldi *et al.*, "Impact of Plasmodium falciparum Coinfection on Longitudinal Epstein-Barr Virus Kinetics in Kenyan Children," *J Infect Dis*, vol. 213, no. 6, Art. no. 6, Mar. 2016, doi: 10.1093/infdis/jiv525.
- [50] G. Gentile and A. Micozzi, "Speculations on the clinical significance of asymptomatic viral infections," *Clinical Microbiology and Infection*, vol. 22, no. 7, Art. no. 7, Jul. 2016, doi: 10.1016/j.cmi.2016.07.016.
- [51] D. Bonsall *et al.*, "Evaluation of Viremia Frequencies of a Novel Human Pegivirus by Using Bioinformatic Screening and PCR.," *Emerg Infect Dis*, vol. 22, no. 4, Art. no. 4, Apr. 2016, doi: 10.3201/eid2204.151812.
- [52] R. Schlaberg *et al.*, "Viral Pathogen Detection by Metagenomics and Pan-Viral Group Polymerase Chain Reaction in Children With Pneumonia Lacking Identifiable Etiology," *J Infect Dis*, vol. 215, no. 9, Art. no. 9, May 2017, doi: 10.1093/infdis/jix148.
- [53] F. E. Chaer and H. M. E. Sahly, "Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity," *The American Journal of Medicine*, vol. 132, no. 4, pp. 437–446, Apr. 2019, doi: 10.1016/j.amjmed.2018.12.011.
- [54] A. S. Muerhoff, G. J. Dawson, and S. M. Desai, "A previously unrecognized sixth genotype of GB virus C revealed by analysis of 5'-untranslated region sequences," *Journal of Medical Virology*, vol. 78, no. 1, Art. no. 1, 2006, doi: 10.1002/jmv.20510.

- [55] Y. Feng *et al.*, "A Novel Genotype of GB Virus C: Its Identification and Predominance among Injecting Drug Users in Yunnan, China," *PLOS ONE*, vol. 6, no. 10, Art. no. 10, Oct. 2011, doi: 10.1371/journal.pone.0021151.
- [56] C. Schwarze-Zander *et al.*, "GB Virus C (GBV-C) Infection in Hepatitis C Virus (HCV)/HIV–Coinfected Patients Receiving HCV Treatment: Importance of the GBV-C Genotype," *J Infect Dis*, vol. 194, no. 4, Art. no. 4, Aug. 2006, doi: 10.1086/505713.
- [57] L. D. D. Mota *et al.*, "Molecular and Clinical Profiles of Human Pegivirus Type 1 Infection in Individuals Living with HIV-1 in the Extreme South of Brazil," *Biomed Res Int*, vol. 2019, Jun. 2019, doi: 10.1155/2019/8048670.
- [58] M. T. M. Giret *et al.*, "Prevalence, Incidence Density, and Genotype Distribution of GB Virus C Infection in a Cohort of Recently HIV-1-Infected Subjects in Sao Paulo, Brazil," *PLOS ONE*, vol. 6, no. 4, Art. no. 4, Apr. 2011, doi: 10.1371/journal.pone.0018407.
- [59] K. Stark, G. Poggensee, M. Höhne, U. Bienzle, I. Kiwelu, and E. Schreier, "Seroepidemiology of TT virus, GBC-C/HGV, and hepatitis viruses B, C, and E among women in a rural area of Tanzania," *J. Med. Virol.*, vol. 62, no. 4, Art. no. 4, Dec. 2000.
- [60] C. Menéndez *et al.*, "Molecular Evidence of Mother-to-Infant Transmission of Hepatitis G Virus among Women without Known Risk Factors for Parenteral Infections," *J Clin Microbiol*, vol. 37, no. 7, pp. 2333–2336, Jul. 1999.
- [61] D. B. Smith *et al.*, "Discrimination of hepatitis G virus/GBV-C geographical variants by analysis of the 5' non-coding region," *Journal of General Virology*, vol. 78, no. 7, Art. no. 7, 1997, doi: 10.1099/0022-1317-78-7-1533.
- [62] Y. Tanaka *et al.*, "African origin of GB virus C/hepatitis G virus 1," *FEBS Letters*, vol. 423, no. 2, Art. no. 2, 1998, doi: 10.1016/S0014-5793(98)00083-0.
- [63] H. F. Liu, J. J. Muyembe-Tamfum, K. Dahan, J. Desmyter, and P. Goubau, "High prevalence of GB virus C/hepatitis G virus in Kinshasa, Democratic Republic of Congo: a phylogenetic analysis," *J. Med. Virol.*, vol. 60, no. 2, Art. no. 2, Feb. 2000.
- [64] R. Tuveri *et al.*, "Prevalence and genetic variants of hepatitis GB-C/HG and TT viruses in Gabon, equatorial Africa," *Am. J. Trop. Med. Hyg.*, vol. 63, no. 3–4, Art. no. 3–4, Oct. 2000, doi: 10.4269/ajtmh.2000.63.192.
- [65] K.-C. Luk *et al.*, "Utility of Metagenomic Next-Generation Sequencing for Characterization of HIV and Human Pegivirus Diversity," *PLOS ONE*, vol. 10, no. 11, Art. no. 11, Nov. 2015, doi: 10.1371/journal.pone.0141723.

- [66] J. C. Iles *et al.*, "Hepatitis C virus infections in the Democratic Republic of Congo exhibit a cohort effect," *Infection, Genetics and Evolution*, vol. 19, pp. 386–394, Oct. 2013, doi: 10.1016/j.meegid.2013.01.021.
- [67] Y. Vitrenko, I. Kostenko, K. Kulebyakina, and K. Sorochnytska, "Prevalence of human pegivirus-1 and sequence variability of its E2 glycoprotein estimated from screening donors of fetal stem cell-containing material," *Virology*, vol. 14, no. 1, p. 167, 31 2017, doi: 10.1186/s12985-017-0837-y.
- [68] E. L. Mohr and J. T. Stapleton, "GB virus type C interactions with HIV: the role of envelope glycoproteins," *J. Viral Hepat.*, vol. 16, no. 11, pp. 757–768, Nov. 2009, doi: 10.1111/j.1365-2893.2009.01194.x.
- [69] L. C. Borish and J. W. Steinke, "2. Cytokines and chemokines," *Journal of Allergy and Clinical Immunology*, vol. 111, no. 2, Supplement 2, Art. no. 2, Supplement 2, Feb. 2003, doi: 10.1067/mai.2003.108.
- [70] R. Domingo-Gonzalez, O. Prince, A. Cooper, and S. A. Khader, "Cytokines and Chemokines in Mycobacterium tuberculosis Infection," *Microbiology Spectrum*, vol. 4, no. 5, Art. no. 5, Oct. 2016, doi: 10.1128/microbiolspec.TBTB2-0018-2016.
- [71] U. Ateba-Ngoa *et al.*, "Cytokine and chemokine profile of the innate and adaptive immune response of schistosoma haematobium and plasmodium falciparum single and co-infected school-aged children from an endemic area of Lambaréné, Gabon," *Malaria Journal*, vol. 14, no. 1, Art. no. 1, Feb. 2015, doi: 10.1186/s12936-015-0608-4.
- [72] S. H. Ross and D. A. Cantrell, "Signaling and Function of Interleukin-2 in T Lymphocytes," *Annu. Rev. Immunol.*, vol. 36, no. 1, Art. no. 1, Apr. 2018, doi: 10.1146/annurev-immunol-042617-053352.
- [73] J. G. Pol, P. Caudana, J. Paillet, E. Piaggio, and G. Kroemer, "Effects of interleukin-2 in immunostimulation and immunosuppression," *J. Exp. Med.*, vol. 217, no. 1, Jan. 2020, doi: 10.1084/jem.20191247.
- [74] A. Fama *et al.*, "Human Pegivirus infection and lymphoma risk and prognosis: a North American study," *British Journal of Haematology*, vol. 182, no. 5, Art. no. 5, 2018, doi: 10.1111/bjh.15416.
- [75] T. Aoshi, S. Koyama, K. Kobiyama, S. Akira, and K. J. Ishii, "Innate and adaptive immune responses to viral infection and vaccination," *Current Opinion in Virology*, vol. 1, no. 4, Art. no. 4, Oct. 2011, doi: 10.1016/j.coviro.2011.07.002.
- [76] C. L. Baldwin *et al.*, "Bovine T cells, B cells, and null cells are transformed by the protozoan parasite Theileria parva," *Infect Immun*, vol. 56, no. 2, Art. no. 2, Feb. 1988.
- [77] J. T. Stapleton *et al.*, "A Novel T Cell Evasion Mechanism in Persistent RNA Virus Infection," *Trans Am*

- [78] N. Bhattarai, J. H. McLinden, J. Xiang, T. M. Kaufman, and J. T. Stapleton, "GB Virus C Envelope Protein E2 Inhibits TCR-Induced IL-2 Production and Alters IL-2–Signaling Pathways," *The Journal of Immunology*, vol. 189, no. 5, Art. no. 5, Sep. 2012, doi: 10.4049/jimmunol.1201324.
- [79] E. Bettelli, M. Oukka, and V. K. Kuchroo, " T_H -17 cells in the circle of immunity and autoimmunity," *Nature Immunology*, vol. 8, no. 4, Art. no. 4, Apr. 2007, doi: 10.1038/ni0407-345.
- [80] P. Meng *et al.*, "Involvement of the Interleukin-23/Interleukin-17 Axis in Chronic Hepatitis C Virus Infection and Its Treatment Responses," *Int J Mol Sci*, vol. 17, no. 7, Art. no. 7, Jul. 2016, doi: 10.3390/ijms17071070.
- [81] F. Y. Yue, A. Merchant, C. M. Kovacs, M. Loutfy, D. Persad, and M. A. Ostrowski, "Virus-Specific Interleukin-17-Producing CD4+ T Cells Are Detectable in Early Human Immunodeficiency Virus Type 1 Infection," *Journal of Virology*, vol. 82, no. 13, Art. no. 13, Jul. 2008, doi: 10.1128/JVI.02550-07.
- [82] V. I. Avelino-Silva *et al.*, "CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients," *PLOS Neglected Tropical Diseases*, vol. 10, no. 12, Art. no. 12, Dec. 2016, doi: 10.1371/journal.pntd.0005219.
- [83] J. H. McLinden *et al.*, "Yellow Fever Virus, but Not Zika Virus or Dengue Virus, Inhibits T-Cell Receptor–Mediated T-Cell Function by an RNA-Based Mechanism," *J Infect Dis*, vol. 216, no. 9, Art. no. 9, Nov. 2017, doi: 10.1093/infdis/jix462.
- [84] L. Rénia and S. M. Potter, "Co-infection of malaria with HIV: an immunological perspective," *Parasite Immunology*, vol. 28, no. 11, Art. no. 11, 2006, doi: 10.1111/j.1365-3024.2006.00903.x.
- [85] K. Rosenke *et al.*, "Plasmodium Parasitemia Associated With Increased Survival in Ebola Virus–Infected Patients," *Clin Infect Dis*, vol. 63, no. 8, Art. no. 8, Oct. 2016, doi: 10.1093/cid/ciw452.
- [86] O. Ouwe-Missi-Oukem-Boyer *et al.*, "Hepatitis C Virus Infection May Lead to Slower Emergence of *P. falciparum* in Blood," *PLoS One*, vol. 6, no. 1, Art. no. 1, Jan. 2011, doi: 10.1371/journal.pone.0016034.

Figures




Figure 1

Unbiased search for RNA molecules encoding human viruses in RNA-seq transcriptomics data. A) Overall prevalence of 9 human viruses detected in 172 whole blood samples B) Number of viral RNA-seq reads detected for each of the identified viruses. Virus names are plotted on the y-axis and proportion (A), number of reads (B) on the x-axis. (C) Distribution of the 9 different viruses across the 28 individuals included. Virus names are plotted on the y-axis and volunteer IDs on the x-axis. Each bar indicates viral reads for an individual. The log viral RNA-seq reads are plotted, in increasing order ranging from 0-3; green indicating low number and red high number of reads.




Figure 2

Proportion of individuals with (purple) and without (grey) HPgV-1 infection. A) Total cohort of 96 vaccinees, B) separated by gender, C) Country of origin, D) HIV-1 infection status. All individuals are between 18-35 years of age. Chi square with Yates correction for group comparisons (*, $P < 0.05$).




Figure 3

Comparisons of HPgV-1 viral loads. No differences in HPgV-1 viral loads between Equatorial Guinea and Togo (A). Two distinct groups with low (blue) and high (brown) viremia (B).

(grey) viremia levels in plasma are found in HPgV-1 infected individuals (B). The two groups were divided based on a cut off value of 600,000 RNA copies/ml plasma.




Figure 4

Phylogenetic inferences of the HPgV-1 isolates based on 5' UTR. Phylogenetic tree was constructed using Neighbour joining method and Kimura two-parameter model of the 5' UTR. The 5' UTR sequences from Tanzania and Equatorial Guinea (n=26) were compared to selected references spanning genotype 1 to 7 from different countries available in the NCBI database. The accession numbers for the reference sequences were: AF488786, AF488789, KC618399, KP710602, U36388, JX494177, Y16436, and MF398547 (Genotype 1, Pink); AB003289, AF104403, D90600, JX494179, MG229668, JX494180, U4402, U59518 (Genotype 2; 2a light brown), MH000566, U59529, U63715, MH053130 (Genotype 2; 2b Brown); AB008335, KR108695, JX494176, D87714 (Genotype 3, Green); AB0188667, AB021287, HQ3311721 (Genotype 4, Maroon); DQ117844, AY949771, AF488796, AF488797 (Genotype 5, Light blue), AB003292, AF177619 (Genotype 6, Bright green); HQ331235, HQ 3312233 (Genotype 7, Golden) and Hepatitis C




Figure 5

Phylogenetic inferences of the HPgV-1 isolates based on E2 region. Phylogenetic tree was constructed using Neighbour joining method and Kimura two-parameter model of the E2 region of HPgV-1. The E2 sequences from Tanzania and Equatorial Guinea (n=9) were compared to selected references spanning genotype 1 to 6 from different countries available in the NCBI database including; KP701602.1, KM670109, U36380, KP710600, KC618399, AB003291 (Genotype 1, Pink); AF121950, MK686596, D90600 (Genotype 2; 2a Brown), U63715 (Genotype 2; 2b Brown) D87714 (Genotype 3, Green); AB0188667 (Genotype 4, Brown); AY94977, KC618401, AY951979 (Genotype 5, Light blue) and AB003292 (Genotype 6, Green). Equatorial Guinean and Tanzanian strains identified in this study are denoted by strain number followed with letters EG or TZ, respectively (Red). Chimpanzee HPgV-1 strain (AF70476, Black) was used as outgroup and U4402 (Genotype 2, Golden) was used for mapping of our sequences to identify regions of similarity. The scale bar under the tree indicates nucleotide substitution per site.




Figure 6

HPgV-1 infection is associated with increased systemic levels of IL-2 and IL-17A. Cytokine, chemokine and growth factors levels were analysed by Luminex and levels compared between HPgV-1 negative (5' UTR-, grey, n=35) and HPgV-1 positive (5' UTR+, purple, n=9) volunteers. Absolute serum concentrations levels (pg/ml) of Interleukin-2 (IL-2) and Interleukin-17A (IL-17A) at samples taken before vaccination are shown. Significantly higher IL-2 and IL-17A are seen in the HPgV-1+ compared to the HPgV-1-. Wilcoxon rank sum test was used to determine significance (p-value * < 0.05) which are indicated on top of top for each group comparison.




Figure 7

HPgV-1 infection status does not impact on anti-PfCSP antibody titres. Total IgG antibodies recognizing full length PfCSP were measured by ELISA in HPgV-1 negative (5' UTR-, grey), HPgV-1 positive (5' UTR+, purple) volunteers. A) Shows baseline (pre-vaccination) anti-PfCSP IgG levels of HPgV-1 negative (n=47) compared to HPgV-1 positive (n=23) volunteers. B) Anti-PfCSP IgG levels at 14 days past last vaccination in HPgV-1 positive individuals (n=17) versus the HPgV-1 negative (n=37) group. (C-D) Comparison of vaccine-induced changes in anti-PfCSP IgG titres as net responses (14 days post last immunization - baseline) as well as fold (14 days post last vaccination/baseline). Only vaccinated individuals were included for 14 days post last immunization, net and fold change responses. One HPgV-1+ individual was not included in these subsequent analyses due to missing antibody data. Log anti-PfCSP titres expressed in arbitrary units are shown. Each point represent an individual, box plot with horizontal bar show median values for each group. Statistical significance was calculated by using Wilcoxon rank sum test (p-value * < 0.05). P values are indicated on top for each group comparison.




Figure 8

HPgV-1 infection does not influence *P. falciparum* pre-patent periods and parasite multiplication rates during CHMI. Parasitemia was determined in whole blood by qPCR and thick blood smear microscopy (TBS). The analysis included only placebo participants, positive and negative for HPgV-1. (A) Shows log-fold change of parasitemia in 48 hours between HPgV-1 negative (5' UTR-, grey, n=13) and HPgV-1 positive (5' UTR+, purple, n=7) volunteers. (B) Comparison of days post CHMI to malaria positivity by microscopy in HPgV-1 negative (5' UTR-, grey, n= 11) and HPgV-1 positive (5' UTR+, purple, n=7). (C) HPgV-1 viral loads before (red) and 28 days post CHMI (green) in HPgV-1 infected individuals. Each point represents an individual, box plots show data distribution with horizontal bar denoting viral load at each visit. Lines connect viremia levels in individuals found positive for HPgV-1 on both time points. Geometric means were compared between groups and unpaired t-test was used to calculate significance. Horizontal bars represent mean with standard deviation Wilcoxon rank sum test was used to compare viremia levels before and after CHMI. P-values are indicated on top of each comparison.




Figure 9

Association of HPgV-1 infection status with PfSPZ CHMI outcome and anti-CSP titers in immunized volunteers. Individuals were treated with either normal saline (placebo) or PfSPZ Vaccine (vaccinees). Presence or absence of malaria parasites was determined in whole blood by thick blood smear microscopy (TBS) and confirmed by qPCR. Total IgG antibodies recognizing full length PfCSP were measured by ELISA. A) Proportion of non-protected (cream) and protected (blue) in vaccinated volunteers with and without HPgV-1 infection. Proportions are indicated inside the bar and volunteer numbers on top. C) Total anti-CSP IgG levels at 14 days past last vaccination in the protected (malaria negative) and non-protected (malaria positive) groups, with and without HPgV-1 infection. Log anti-PfCSP titres expressed in O.D units are shown. Each point represent an individual, and box plot with horizontal bar show median values for each group. Chi square with Yates correction was used for group comparisons of categorical values (*, $P < 0.05$). Wilcoxon rank sum test was used to compare anti-CSP titres in the two groups. P values are indicated on top of each comparison.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Sup.Table1revised.docx](#)
- [Sup.Fig1.pdf](#)
- [Sup.Fig2.pdf](#)
- [Sup.Fig3.pdf](#)
- [Sup.Fig4.pdf](#)